Optimal Pharmacologic Treatment Strategies in Obesity and Type 2 Diabetes
AbstractThe prevalence of obesity has increased to pandemic levels worldwide and is related to increased risk of morbidity and mortality. Metabolic comorbidities are commonly associated with obesity and include metabolic syndrome, pre-diabetes, and type 2 diabetes. Even if the prevalence of obesity remains stable until 2030, the anticipated numbers of people with diabetes will more than double as a consequence of population aging and urbanization. Weight reduction is integral in the prevention of diabetes among obese adults with pre-diabetes. Lifestyle intervention and weight reduction are also key in the management of type 2 diabetes. Weight loss is challenging for most obese patients, but for those with diabetes, it can pose an even greater challenge due to the weight gain associated with many treatment regimens. This article will review optimal treatment strategies for patients with comorbid obesity and type 2 diabetes. The role of anti-obesity agents in diabetes will also be reviewed. This literature review will provide readers with current strategies for the pharmacologic treatment of obesity and diabetes with a focus on the weight outcomes related to diabetes treatments. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Goswami, G.; Shinkazh, N.; Davis, N. Optimal Pharmacologic Treatment Strategies in Obesity and Type 2 Diabetes. J. Clin. Med. 2014, 3, 595-613.
Goswami G, Shinkazh N, Davis N. Optimal Pharmacologic Treatment Strategies in Obesity and Type 2 Diabetes. Journal of Clinical Medicine. 2014; 3(2):595-613.Chicago/Turabian Style
Goswami, Gayotri; Shinkazh, Nataliya; Davis, Nichola. 2014. "Optimal Pharmacologic Treatment Strategies in Obesity and Type 2 Diabetes." J. Clin. Med. 3, no. 2: 595-613.